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Abstract
Background: Reducing the number of people with undiagnosed HIV infection is a major goal of HIV control and
prevention efforts in Europe and elsewhere. We analysed data from a large multi-city European bio-behavioural
survey conducted among Men who have Sex with Men (MSM) for previously undiagnosed HIV infections, and
aimed to characterise undiagnosed MSM who test less frequently than recommended.
Methods: Data on sexual behaviours and social characteristics of MSM with undiagnosed HIV infection from Sialon
II, a bio-behavioural cross-sectional survey conducted in 13 European cities in 2013/2014, were compared with HIV-
negative MSM. Based on reported HIV-testing patterns, we distinguished two subgroups: MSM with a negative HIV
test result within 12 months prior to the study, i.e. undiagnosed incident infection, and HIV positive MSM with
unknown onset of infection. Bivariate and multivariate associations of explanatory variables were analysed. Distinct
multivariate multi-level random-intercept models were estimated for the entire group and both subgroups.
Results: Among 497 participants with HIV-reactive specimens, 234 (47.1%) were classified as previously diagnosed,
106 (21.3%) as incident, and 58 (11.7%) as unknown onset based on self-reported status and testing history. MSM
with incident HIV infection were twice as likely (odds ratio (OR) = 2.22, 95% confidence interval (95%CI): 1.17–4.21)
to have used recreational substances during their last anal sex encounter and four times more likely (OR = 3.94,
95%CI: 2.14–7.27) not to discuss their HIV status with the last anal sex partner(s). MSM with unknown onset of HIV
infection were 3.6 times more likely (OR = 3.61, 95%CI: 1.74–7.50) to report testing for a sexually transmitted
infection (STI) during the last 12 months.
Conclusions: Approximately one third of the study participants who are living with HIV were unaware of their infection.
Almost two-third (65%) of those with undiagnosed HIV appeared to have acquired the infection recently, emphasizing a
need for more frequent testing. Men with the identified behavioural characteristics could be considered as primary target
group for HIV Pre-Exposure Prophylaxis (PrEP) to avoid HIV infection. The increased odds of those with unknown onset of
HIV infection to have had an STI test in the past year strongly suggests a lost opportunity to offer HIV testing.
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Background
In recent years a range of efforts and new initiatives
have been implemented across Europe to increase Hu-
man Immunodeficiency Virus (HIV) testing among
key populations and to reduce the number of undiag-
nosed HIV infections and late diagnoses [1]. Despite
some progress in terms of increased testing uptake, a
recent report from the European Centre for Disease
Prevention and Control (ECDC) estimates that the
proportion of undiagnosed HIV among Men having
Sex with Men (MSM) in six European countries is 17%
[2]. This falls short of the internationally agreed goal
of diagnosing at least 90% of the people who are in-
fected [3]. Furthermore, approximately one third of
HIV diagnoses among MSM in the European Union
(EU) are late (CD4 < 350 cells/μl at diagnosis). Redu-
cing late HIV diagnoses would result in substantial in-
dividual (i.e. reduced morbidity and mortality) and
public health benefits (reduced transmission and re-
duction of health care costs) [4, 5]. In addition to ad-
verse health outcomes, late diagnoses and late
initiation of antiretroviral therapy are associated with
increased risks for transmitting HIV unknowingly to
sexual partners.
In countries with unrestricted access to antiretroviral
treatment undiagnosed HIV infections are thought to be
the main sources of new HIV infections. Early diagnosis
of HIV and successful treatment are thus important for
the successful management of the disease in individual
patients as well as major tools supporting the implemen-
tation of the WHO strategy for anti-retroviral treatment
as prevention [3, 6, 7].
The level of undiagnosed infections is driven by HIV
incidence on the one hand and by the testing rate on the
other. Factors increasing HIV incidence are likely to
contribute to the increased level of undiagnosed infec-
tions, even among frequent testers. Additionally, barriers
to testing and low testing uptake may cause accumula-
tion of infections, including late stage infections [8, 9].
Little is known about the characteristics and sexual be-
haviours of people with undiagnosed infections. Some
information can be retrieved from HIV testing sites from
people newly diagnosed with HIV [10–12], although the
demographic data collected and analysed are quite lim-
ited from such clinical sites [13, 14]. People presenting
for testing self-select and therefore such samples may be
biased. Another way to collect such information is from
longitudinal cohort studies including HIV-uninfected
people at risk for HIV. However, such studies are time
consuming, costly, and rarely conducted in Europe. In
addition, participants may not be representative of the
population at risk in real world settings. Bio-behavioural
studies, such as the multi-city Sialon II study, may
therefore be better suited to systematically collect
information on people who are unknowingly infected
with HIV [15, 16] with more scientific rigour and fewer
biases.
In general, the risk of HIV infection among MSM is
associated with sexual risk practices such as the lack of
condom use, number of partners with whom condom-
less anal intercourse is practised, drug use associated
with sex, and attending gay sex venues where risky sex-
ual behaviours are part of the sub-culture [17]. However,
such risk practices are driven by a complex set of inter-
twined factors, ranging from the personal level factors
(e.g. age, personal skills and self-efficacy, mental health)
to interpersonal factors (partner dynamics, communica-
tion and negotiation on sex practices), to community
and service provision-related factors (social and sexual
norms, perceived homonegativity in communities; access
to testing and other medical services) and structural fac-
tors (policies and legislation). The intersection of these
factors is further shaped by high HIV prevalence in sub-
groups of MSM [18].
Barriers to HIV testing have also been extensively de-
scribed in the literature: testing for HIV is more likely
for individuals who perceive themselves at risk for HIV
and who anticipate personal benefits from testing, while
fears of consequences of receiving an HIV diagnosis hin-
ders HIV testing. The latter has been shown to be asso-
ciated with fear of discrimination and personal rejection
[19, 20]. Research has also shown that multiple
social-cognitive factors (e.g. knowledge, attitudes, per-
ceived behavioural control) play a role in explaining test-
ing for HIV and sexually transmitted infections (STI)
among MSM [20]. In addition to patient-level factors, a
review demonstrated the influence of health-systems
and structural factors on uptake of HIV testing [8].
The present study used data from a large multi-city
European bio-behavioural survey conducted among
MSM within the framework of the European Public
Health Project Sialon II. The analysis has two objectives
– 1) to identify factors correlating with early undiag-
nosed infections among testers, which are most likely
driven by HIV incidence among repeat testers; and 2) to
characterise groups that are not adhering to testing rec-
ommendations in order to properly inform appropriate
testing campaigns targeted towards them.
Methods
Study design and procedures
Sialon II was a multi-site bio-behavioural cross-sectional
survey carried out in 13 European cities. The cities were:
Brussels (Belgium), Sofia (Bulgaria), Hamburg (Germany),
Verona (Italy), Vilnius (Lithuania), Warsaw (Poland),
Lisbon (Portugal), Bucharest (Romania), Bratislava
(Slovakia), Ljubljana (Slovenia), Barcelona (Spain),
Stockholm (Sweden), and Brighton (UK). In 2013/2014,
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MSM were recruited to participate in the survey using
time-location-sampling (TLS) in community-based set-
tings in nine European cities, and using respondent-dri-
ven-sampling (RDS) in social networks of MSM in four
European cities (Bucharest, Bratislava, Verona, Vilnius). In
TLS cities participants were recruited during 2013, in
RDS cities recruitment started in 2013 and finished in
2014. Recruitment methods, study procedures, questions
asked as well as sample collection and testing have been
described in detail elsewhere [21]. The study protocol was
approved by ethical review committees in all participating
countries and by the WHO Research Project Review Panel
(WHO-RP2) and the WHO Research Ethics Review
Committee (WHO-ERC) before the data collection phase.
The bio-behavioural survey data generated from the
Sialon II project provided the opportunity to combine
data on testing history and self-reported HIV test result,
and to link them with the laboratory determined HIV
status to identify men with an undiagnosed HIV infec-
tion at the time of the survey implementation. In this
analysis, sexual behaviours and social characteristics of
these men with undiagnosed HIV infection are assessed
and compared with their uninfected peers.
Measures
Participants filled in a short questionnaire and provided
either an oral fluid (in TLS cities) or blood (in RDS
cities) specimen for HIV antibody testing. Based on
self-reported HIV status and the HIV testing result of
the collected specimen, participants were classified as
HIV-uninfected (nHIV), previously diagnosed with HIV
infection (pHIV), and HIV-infected but as yet undiag-
nosed (uHIV). As far as the time of HIV diagnosis is
concerned, three different patterns can be distinguished:
1) early diagnosis, when testing is predominantly trig-
gered by symptoms of acute HIV infection and/or
awareness of transmission risk; 2) intermediate diagno-
sis, when testing is triggered by health concerns not im-
mediately related to acute HIV disease or transmission
risk awareness; 3) late diagnosis, often triggered by
symptoms or health complaints associated with compro-
mised immune status. These three patterns may be asso-
ciated with different demographic and behavioural
characteristics (see below). Since data on HIV testing in-
tentions were not collected, we used HIV testing history
to distinguish between a group with likely high testing
frequency and incident HIV infection (uHIVinc -
negative test result reported within 12 months before
the study specimen was collected) and MSM who were
tested a longer time ago or never tested for HIV infec-
tion of unknown onset (uHIVunk). The uHIVinc sub-
group may represent pattern 1 and partially pattern 2
testers, while the uHIVunk subgroup may represent the
complementary part of pattern 2 and pattern 3 testers.
The following questionnaire items were used to deter-
mine if the case had been previously diagnosed: a ques-
tion whether and if yes, when the last HIV antibody test
was performed and a question on the result of the last
HIV antibody test. If these questions were not answered
or information was inconsistent HIV status knowledge
was classified as undetermined and respondents were
excluded from the analysis. In addition, participants re-
cruited in Sofia had to be excluded from the two test re-
cency subgroup analyses because the answers were
invalid due to an incorrect translation of the respective
question.
Lab testing of biological samples
In line with the TLS protocols, oral fluid (OF) specimens
were collected and tested for HIV antibodies using Gen-
screen HIV 1/2 version 2, BIO-RAD. A total IgG anti-
bodies ELISA test Human IgG ELISA Kit 1 × 96,
Quantitative / Immunology Consultants Laboratory was
used for OF specimen testing suitability and quality con-
trol. All HIV-reactive specimens were re-tested with Vir-
onostika HIV Ag/Ab, bioMérieux. Specimens tested
positive with the first HIV ELISA test, but negative with
the second were classified as negative.
MSM who participated to the survey in cities where
RDS was used as recruitment method received pre/
post-test counselling during the enrolment and follow
up process. Blood samples were collected and serum ex-
tracted in line with the local standard procedures. Serum
samples were tested with an HIV 4th generation ELISA/
CLIA screening test. A Western blot test was used to
confirm positive cases. In case of a confirmed HIV posi-
tive result, a referral procedure was put in place in line
with the local standard procedures to ensure linkage to
care and proper case management.
Secondary variables
Based on published literature on factors associated with
HIV acquisition risk, undiagnosed HIV infection or in-
frequent HIV testing and late diagnosis among MSM (as
mentioned in the introduction), associations of uHIV,
uHIVinc and uHIVunk status were analysed with:
– Demographic variables such as age (calculated using
the self-reported year of birth), education level (sec-
ondary school or lower, high school or post-
secondary or university/ higher), migration status
(native: born & living in the study country; emigrant:
born in the study country & living abroad; immi-
grant: born abroad & living in the study country;
visitor: born & living abroad);
– Behavioural variables such as number of sexual
partners and number of partners with whom
condomless anal intercourse (AI) had been practiced
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in the previous 6 months, frequency of visiting gay
sex venues in the last 3 months, type and number of
drugs used during last AI (categorised as alcohol;
cannabis; sexual performance enhancing substances:
erectile dysfunction medication and inhaled amyl
nitrite; party drugs: cocaine, ecstasy, amphetamines;
chemsex drugs: GHB, ketamine, mephedrone,
crystal meth);
– Type of partners for last AI (steady, non-steady,
more than one), self-reported HIV serostatus dis-
closure to the last AI partner, sexual role during last
AI (top, bottom, versatile), condom use during last
AI;
– HIV and STI testing in the previous 12 months, and
“outness” about sexual orientation towards relatives,
friends, and co-workers.
The self-administered questionnaire filled-in by the
study participants is available as Additional file 1.
Statistical analysis
We conducted analyses of bivariate and multivariate as-
sociations of explanatory variables with uHIV, and the
two subgroups uHIVinc and uHIVunk, using nHIV for
comparison. For the two subgroups, the comparison
group was also determined by their last reported HIV
test date, i.e. the comparison group for uHIVinc was
tested negative within the previous 12 months, and the
comparison group for uHIVunk was never tested or
tested more than 12 months ago.
A multivariate multi-level logistic random-intercept
model (random effect of study site) was estimated to ac-
count for the hierarchical structure of the data [22]. The
multi-level analysis was conducted to identify factors as-
sociated with each subgroup separately and with the
combined group. Predictors associated with the outcome
variable with a probability < 0.05 were considered
significant.
Stata Version 14.2 was used (College Station, TX: Sta-
taCorp LP).
The dataset used for the analysis presented in this
manuscript is available as Additional file 2. The Stata
syntax of the analysis is available as Additional file 3.
Results
Study sample
A detailed description of the study sample has been pub-
lished in the study report [23]. At most study sites, ap-
proximately 400 men had been recruited as requested by
the study protocol, with exception of Bucharest, where
only 183 participants were enrolled. There were significant
age differences between study sites. The proportion of
study participants tested for HIV in the last 12 months be-
fore completing the study questionnaire among those not
known to have been diagnosed with HIV ranged between
35.5% in Bratislava and 66.2% in Barcelona (see Table 1).
Table 1 Sialon II study participants by study site, testing history and measured HIV status after exclusion of participants already
known to have HIV and with indeterminate HIV status knowledge
city HIV
negative
(n)
percentage
tested for HIV
in the last
12 months (%)
undiagnosed
HIV infection
(n)
percentage
with
undiagnosed
HIV (%)
undiagnosed HIV,
negative HIV pre-test
within recent
12 months (n)
undiagnosed HIV
infection, no pre-test or
test longer ago than
12 months (n)
percentage of
undiagnosed HIV
that may not be
recent (%)
Total
(N)
Barcelona 334 66.2% 21 5.9% 16 5 23.8% 355
Bratislava 376 35.5% 15 3.8% 6 9 60.0% 391
Brighton 331 56.7% 15 4.3% 10 5 33.3% 346
Brussels 327 63.5% 7 2.1% 5 2 28.6% 334
Bucharest 146 42.9% 15 9.3% 7 8 53.3% 161
Hamburg 336 52.1% 15 4.3% 11 4 26.7% 351
Lisbon 300 63.8% 29 8.8% 23 6 20.7% 329
Ljubljana 329 50.9% 7 2.1% 5 2 28.6% 336
Sofiaa 344 12 3.4% 356
Stockholm 334 49.9% 3 0.9% 2 1 33.3% 337
Verona 367 41.9% 10 2.7% 2 8 80.0% 377
Vilnius 314 38.9% 5 1.6% 2 3 60.0% 319
Warsaw 346 57.9% 22 6.0% 17 5 22.7% 368
Total 4184 176 4.0% 4360
Total w/o Sofia 3840 51.9% 164 106 58 33.0% 4004
adata on recency of last HIV testing are missing for Sofia due to incorrect translation of the question in the Bulgarian questionnaire version
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Formative research conducted in preparation of the
bio-behavioural survey established that HIV testing
sites, including sites providing free and anonymous
HIV testing and rapid testing existed in all study cit-
ies at the time when study recruitment occurred [24].
Further qualitative assessments of gay-friendliness, ac-
cessibility and acceptability of available testing ser-
vices were not conducted. HIV home tests and home
collection tests were unavailable.
A valid HIV test result was available for 4716
participants. The antibody test result was non-reactive
for 4219 specimens, and reactive for 497 specimens
(11.8%). From the 4219 participants with non-reactive
specimens 4184 (99%) were classified as nHIV, 35
were classified as indeterminate due to conflicting or
missing self-reported data on HIV infection status.
From the participants with reactive specimens 234
(47%) were classified as pHIV, 102 (20.5%) as uHI-
Vinc, and 49 (9.9%) as uHIVunk based on
self-reported infection status and testing history.
Twelve participants from Sofia with undiagnosed HIV
infection could not be classified in these two sub-
groups. The remaining 100 (20.1%) participants with
reactive specimens had to be classified as indetermin-
ate based on questionnaire data due to incomplete in-
formation on testing history and status knowledge
(e.g. non-response to the question on previous HIV
test and/or test result).
A weak positive correlation between the percentage of
the participants tested for HIV by study site in the re-
cent 12 months and the percentage of undiagnosed
HIV in the study sites was observed (r = .275 - see
Table 1).
Undiagnosed HIV infections and associations with
demographics and behaviours
The distribution of all and of undiagnosed infections by
age group is shown in Fig. 1.
The percentage of undiagnosed infections from all
prevalent infections is approaching 50% in age groups
younger than 35 years-old and declines to less than 30%
in older age groups.
Table 1 shows the distribution of undiagnosed HIV in-
fections by study sites. The proportion of study partici-
pants with undiagnosed HIV infection ranged from 0.9%
in Stockholm to 9.3% in Bucharest. The overall propor-
tion of undiagnosed HIV infections among men without
a recent test result was almost one-third of the undiag-
nosed infections, ranging from 20.7% in Lisbon to 80%
in Verona. The proportions of undiagnosed HIV among
infrequent testers were consistently higher than 50% in
the four cities Bratislava, Bucharest, Vilnius and Verona,
in which RDS was used for recruitment.
Table 2 shows the reported last test dates among study
participants who did not report having HIV or a last
HIV test within the 12 months before they were re-
cruited to the Sialon study.
Table 3 shows results of bivariate analysis of associa-
tions between potential explanatory variables and the
outcomes 1) undiagnosed HIV infection, acquired within
the previous 12 months - uHIVinc; 2) undiagnosed HIV
infection of unknown onset - uHIVunk; 3) undiagnosed
Fig. 1 Age distribution and prevalence of HIV infection and undiagnosed HIV by age group in the Sialon II participants, Sialon II biobehavioural
survey, 2013–2014
Marcus et al. BMC Infectious Diseases  (2018) 18:368 Page 5 of 15
HIV infection irrespective of date of previous HIV test
(1 and 2 combined - uHIV).
Compared with HIV uninfected survey participants,
men assigned to the uHIVinc group were more likely to
be 25–44 years of age (compared to the reference age
group 18–24), and showed higher odds for the use of
drugs during last anal sex, they were less likely to have
disclosed their presumed negative HIV serostatus to
their last anal sex partner(s), more likely to have been
versatile during their last anal sex encounter, and more
Table 2 Distribution of Sialon II study participants who were not aware of having HIV by laboratory-determined HIV status and year
of last HIV test - overall and by test recency group
uHIV - study sample uHIVunk - last HIV test not within 12 months of recruitment into the study
Year of last reported test HIV negative HIV positive,
undiagnosed
Year of last reported test HIV negative HIV positive,
undiagnosed
1987 1 0 1987 1 0
1988 1 0 1988 1 0
1989 2 0 1989 2 0
1990 5 0 1990 5 0
1991 1 0 1991 1 0
1992 3 0 1992 3 0
1993 2 0 1993 2 0
1994 1 0 1994 1 0
1995 4 1 1995 4 1
1996 2 1 1996 2 1
1997 5 1 1997 5 1
1998 7 0 1998 7 0
1999 6 0 1999 6 0
2000 18 0 2000 18 0
2001 10 0 2001 10 0
2002 13 1 2002 13 1
2003 15 0 2003 15 0
2004 14 0 2004 14 0
2005 39 2 2005 39 2
2006 22 2 2006 22 2
2007 39 0 2007 39 0
2008 61 0 2008 61 0
2009 80 4 2009 80 4
2010 151 13 2010 151 13
2011 267 8 2011 267 8
2012 785 47 2012 205 10
2013 1306 70 2013 30 2
2014 32 0 never tested/year missing 864 13
year missinga 1292 26 Total 1868 58
Total 4184 176
uHIVinc - last test within 12 months before recruitment into the study
2012 580 37
2013 1276 68
2014 32 0
year missing, test within the last 12 months reported 84 1
Total 1972 106
aincludes 356 participants from Sofia whose last HIV test date could not be determined
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Table 3 Associations between demographic and behaviour variables and undiagnosed HIV infection in participants of the European
Sialon II biobehavioural survey
uHIVinc uHIVunk uHIV N
Odds
Ratio
p-
value
[95% Conf.
Interval]
Odds
Ratio
p-
value
[95% Conf.
Interval]
Odds
Ratio
p-
value
[95% Conf.
Interval]
Age group 18–24 ref. 923
25–34 3.34 0.00 1.58 7.07 1.69 0.25 0.70 4.07 2.65 0.00 1.56 4.50 1730
35–44 3.05 0.01 1.37 6.80 2.82 0.02 1.18 6.73 2.90 0.00 1.66 5.06 970
45–54 2.37 0.07 0.94 5.97 2.00 0.19 0.72 5.59 2.16 0.02 1.11 4.19 488
55+ 1.36 0.66 0.35 5.20 1.39 0.64 0.35 5.46 1.34 0.54 0.52 3.44 244
Migration status native ref. 3565
emigrant 2.14 0.20 0.63 7.20 6.78 0.02 1.45 31.84 3.06 0.01 1.29 7.27 54
immigrant 1.03 0.92 0.58 1.81 1.32 0.48 0.61 2.83 1.17 0.49 0.75 1.84 503
visitor: born & live
abroad
0.70 0.45 0.28 1.96 1.78 0.73 0.19 3.26 0.78 0.53 0.36 1.69 226
Any STI test in last 12 months no ref. 2249
yes 1.15 0.62 0.67 1.95 3.01 0.00 1.56 5.84 1.94 0.00 1.42 2.66 2007
STI diagnoses no diagnosis ref. 3946
1 diagnosis 0.71 0.36 0.34 1.48 6.31 0.00 2.10 18.05 1.24 0.43 0.72 2.14 310
2 diagnoses 1.03 0.97 0.31 3.35 4.96 0.14 0.60 41.01 1.40 0.52 0.50 3.88 74
3 diagnoses 1.07 0.95 0.14 8.10 1.00 – – – 1.44 0.73 0.19 10.88 18
4 diagnoses 1.00 – – – 1.00 – – – 1.00 – – – 8
5 diagnoses 6.04 0.12 0.62 58.66 1.00 – – – 8.15 0.07 0.84 78.82 4
any STI diagnosis 0.82 0.52 0.46 1.49 5.98 0.00 2.23 16.06 1.31 0.26 0.82 2.09 414
Number of sex partners no partner ref. 269
1 partner 0.64 0.38 0.24 1.72 4.82 0.13 0.62 37.34 1.37 0.46 0.59 3.17 819
2–3 partners 0.78 0.59 0.31 1.96 3.73 0.21 0.47 29.34 1.34 0.48 0.59 3.07 981
4–5 partners 0.79 0.63 0.30 2.08 4.57 0.16 0.56 37.45 1.49 0.36 0.64 3.51 626
6–10 partners 0.67 0.43 0.25 1.80 8.35 0.04 1.08 64.42 1.62 0.26 0.70 3.73 701
> 10 partners 0.99 0.89 0.40 2.47 10.21 0.03 1.30 79.90 2.28 0.05 1.01 5.14 748
Number of partners with
condomless anal intercourse
no partner ref. 1499
1 partner 0.57 0.06 0.32 1.02 1.30 0.54 0.57 2.96 0.85 0.49 0.55 1.33 1108
2–3 partners 1.13 0.65 0.67 1.90 2.11 0.07 0.95 4.68 1.36 0.16 0.89 2.07 839
4–5 partners 0.67 0.46 0.24 1.92 5.03 0.00 1.92 13.16 1.50 0.22 0.79 2.85 235
6–10 partners 1.17 0.75 0.45 3.05 2.94 0.10 0.80 10.67 1.79 0.09 0.92 3.50 182
> 10 partners 2.68 0.02 1.14 6.30 12.84 0.00 3.75 43.93 3.55 0.00 1.83 6.88 106
Type of partners in last
6 months
steady partner(s) ref. 653
non-steady
partner(s)
1.18 0.65 0.58 2.38 1.08 0.86 0.49 2.35 1.12 0.66 0.68 1.85 1297
s + ns partner(s) 1.31 0.42 0.68 2.55 1.00 1.00 0.49 2.04 1.23 0.39 0.77 1.97 2001
no partner 1.67 0.35 0.56 4.97 0.22 0.15 0.03 1.71 0.78 0.60 0.31 1.95 216
Anal sex in last 6 months no anal sex ref. 857
anal intercourse
(with condom)
0.87 0.65 0.47 1.59 1.21 0.67 0.50 2.95 1.12 0.65 0.69 1.84 1005
condomless anal
intercourse
0.80 0.43 0.47 1.38 1.95 0.05 0.99 3.85 1.30 0.21 0.86 1.98 2498
Type of partner at last anal sex steady partner ref. 1880
non-steady partner 1.01 0.96 0.65 1.67 1.04 0.07 0.95 3.17 1.30 0.13 0.93 1.82 1760
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likely to have had more than 10 partners in the last
6 months with whom they had condomless anal
intercourse.
Men assigned to the uHIVunk group were more
likely to be older (age groups 35–44) than
HIV-uninfected men who had not been tested for HIV
in the last 12 months, to report any condomless anal
intercourse in the last 6 months, and to have higher
numbers of partners in the last 6 months with whom
they had condomless anal sex, they were more likely to
have been tested for and diagnosed with an STI in the
last 12 months, and more likely to be an emigrant on
home visit to his country of origin, but they were
mostly inconspicuous in terms of substance use and
most other potential explanatory variables.
In multivariate analysis assignment to the uHIVinc group
remained significantly associated with age 25–34, and ver-
satility, lack of serostatus disclosure, and use of party and
sexual performance enhancing drugs during the last anal
sex event (see Table 4). The only factors remaining associ-
ated with uHIVunk in multivariate analysis were age 35–
54, higher number of partners with whom condomless anal
sex had been practiced in the last 6 months, and more fre-
quent STI testing in the last 12 months.
Education, migration status, outness, frequency of visit-
ing gay sex venues in the last 6 months, partnership
Table 3 Associations between demographic and behaviour variables and undiagnosed HIV infection in participants of the European
Sialon II biobehavioural survey (Continued)
uHIVinc uHIVunk uHIV N
Odds
Ratio
p-
value
[95% Conf.
Interval]
Odds
Ratio
p-
value
[95% Conf.
Interval]
Odds
Ratio
p-
value
[95% Conf.
Interval]
more than one partner 2.06 0.04 1.03 4.11 2.33 0.13 0.77 7.04 2.22 0.01 1.24 3.97 207
Sexual role with last AI partner top ref. 1324
bottom 1.11 0.71 0.64 1.94 1.07 0.93 0.49 1.94 0.98 0.93 0.65 1.48 1265
versatile 2.08 0.00 1.27 3.42 1.00 1.00 0.48 2.09 1.61 0.02 1.09 2.37 1035
Serostatus disclosure to last AI
partner
no disclosure ref. 2400
disclosure 0.27 0.00 0.15 0.48 1.18 0.82 0.56 2.06 0.50 0.00 0.33 0.75 1262
Number of drugs consumed at
last anal sex
0 ref. 1959
1 2.31 0.00 1.37 3.91 0.91 0.75 0.50 1.66 1.50 0.03 1.04 2.16 1394
2 2.98 0.00 1.58 5.61 0.99 0.99 0.41 2.42 1.74 0.02 1.08 2.79 516
3 4.30 0.00 2.03 9.09 1.00 – – – 2.31 0.01 1.19 4.49 167
4 5.59 0.00 1.79 11.80 2.04 0.50 0.26 15.97 3.33 0.00 1.46 7.55 76
5 4.69 0.02 1.32 16.70 1.00 – – – 2.66 0.11 0.80 8.87 40
6 9.38 0.01 1.89 54.64 7.66 0.07 0.83 70.60 8.19 0.00 2.25 29.82 15
7 4.17 0.18 0.51 34.29 1.00 – – – 2.98 0.30 0.38 23.46 12
8 1.00 – – – 1.00 – – – 1.00 – – – 6
9 18.76 0.02 1.64 214.37 1.00 – – – 10.93 0.04 1.12 106.62 4
Type of drugs no party drug ref. 3875
party 2.90 0.00 1.77 4.77 0.36 0.32 0.05 2.66 2.04 0.00 1.29 3.22 307
no chemsex drug ref. 4063
chemsex 2.14 0.04 1.04 4.39 1.89 0.54 0.25 14.45 2.42 0.01 1.24 4.71 111
no sexual performance
substance
ref. 3326
sexual performance
substance
2.41 0.00 1.61 3.61 1.79 0.07 0.95 3.37 2.15 0.00 1.55 2.98 853
no cannabis ref. 3869
cannabis 2.20 0.01 1.27 3.79 0.89 0.85 0.27 2.91 1.75 0.02 1.08 2.83 304
no alcohol ref. 2.324
alcohol 1.90 0.00 1.26 2.84 0.70 0.23 0.40 1.25 1.33 0.07 0.98 1.80 1859
Satisfaction with sex life unsatisfied ref. 950
satisfied 1.70 0.08 0.94 3.08 1.16 0.67 0.59 2.27 1.48 0.06 0.98 2.22 3.124
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Table 4 Multivariate multilevel models to estimate associations between undiagnoseda HIV infection and demographic and
behavioural parameters among participants of the Sialon II study
Odds Ratio p-value [95% Conf. Interval]
uHIVinc (n = 1713)
Age group 18–24 ref.
25–34 2.27 0.04 1.03 4.99
35–44 1.62 0.29 0.67 3.90
45–54 1.37 0.56 0.48 3.96
55+ 1.08 0.91 0.26 4.46
Sexual role with last AI partner top ref.
bottom 1.12 0.73 0.60 2.07
versatile 2.05 0.01 1.18 3.55
Type of drugs during last anal sex no use of ecstasy, cocaine, amphetamine ref.
ecstasy, cocaine, amphetamine 2.22 0.02 1.17 4.21
no use of sexual performance substances
(poppers, erectile dysfunction medication)
ref.
sexual performance substances (poppers,
erectile dysfunction medication)
1.96 0.01 1.17 3.28
Serostatus disclosure to last AI partner disclosure ref.
no disclosure 3.94 0.00 2.14 7.27
_cons 0.01 0.00 0.00 0.01
city 0.40 – 0.11 1.45
uHIVunk (n = 1639)
Age group 18–24 ref.
25–34 2.00 0.16 0.76 5.27
35–44 3.73 0.01 1.41 9.84
45–54 3.31 0.04 1.08 10.12
55+ 0.90 0.93 0.10 7.84
Number of partners with condomless anal intercourse no partner ref.
1 partner 1.46 0.38 0.63 3.36
2–3 partners 2.66 0.02 1.17 6.04
4–5 partners 6.08 0.00 2.26 16.40
6–10 partners 2.01 0.38 0.43 9.44
> 10 partners 12.83 0.00 3.60 45.65
STI testing in last 12 months no testing ref.
any STI testing 3.61 0.00 1.74 7.50
_cons 0.02 0.00 0.01 0.07
city 0.00 – – –
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status, type of partner for the last anal intercourse, con-
dom use during last anal intercourse, and sexual role dur-
ing last anal intercourse were not significantly different
between men with and without undiagnosed HIV
infection.
Discussion
Approximately one third of the study participants who
were living with HIV and for whom their HIV status
knowledge could be assessed were unaware of being in-
fected. This is much higher than proportions reported
from some modelling studies or estimates reported to
ECDC for Dublin Declaration monitoring [2, 25, 26].
This apparent contradiction is likely explained by an age
related effect in our sample: as we can show in our ana-
lyses, the proportion of undiagnosed HIV is highly
age-dependent. A large proportion of MSM living with
HIV in the Western European countries, where the HIV
epidemic amongst MSM started already in the 1980s, is
already older than 40 years. These higher age groups are
underrepresented among the visitors of gay venues that
often cater to younger MSM clients. When the different
age composition of the Sialon sample and the MSM
population in modelling studies are considered, the
results in terms of the proportions of undiagnosed infec-
tions are essentially comparable [own unpublished com-
parisons between modelling results of the German
undiagnosed fraction and Sialon results for Hamburg].
Contrastingly, in Eastern European countries, where the
HIV epidemic among MSM is more recent and the frac-
tion of older infections in aging survivors is much
smaller, the Sialon results are comparable with model-
ling studies [27]. Another aspect that needs to be con-
sidered when comparing Sialon II results with national
modelling studies is that Sialon II was conducted in
large cities while modelling studies include whole coun-
tries. Regardless, our findings underline that in many
settings where MSM congregate and seek sexual part-
ners, a considerable proportion of those who are living
with HIV are unaware of their HIV status.
Our analysis further shows that men with an undiag-
nosed HIV infection are a heterogeneous group of
people. In our European multi-city sample, approxi-
mately two-third of those with undiagnosed HIV infec-
tion reported to have received a negative HIV test result
in the previous 12 months, indicating the relatively re-
cent acquisition of the infection and substantial inci-
dence in this group. Moreover, this subgroup of men
Table 4 Multivariate multilevel models to estimate associations between undiagnoseda HIV infection and demographic and
behavioural parameters among participants of the Sialon II study (Continued)
Odds Ratio p-value [95% Conf. Interval]
uHIV (n = 3745)
Age group 18–24 ref.
25–34 2.36 0.00 1.33 4.19
35–44 2.22 0.01 1.19 4.13
45–54 1.90 0.09 0.91 3.94
55+ 0.85 0.78 0.27 2.66
HIV test in last 12 months and knowing the result not tested ref.
tested and knowing the result 1.51 0.03 1.04 2.19
Number of partners with condomless anal intercourse no partner ref.
1 partner 0.85 0.50 0.54 1.35
2–3 partners 1.28 0.30 0.81 2.03
4–5 partners 1.35 0.39 0.68 2.69
6–10 partners 1.56 0.25 0.74 3.29
> 10 partners 2.80 0.01 1.34 5.85
Type of drugs during last anal sex no use of sexual performance substances
(poppers, erectile dysfunction medication)
ref.
sexual performance substances (poppers,
erectile dysfunction medication)
1.91 0.00 1.32 2.76
_cons 0.01 0.00 0.01 0.02
city 0.32 – 0.10 1.01
athe three models estimate associations in three groups:
uHIVinc – undiagnosed HIV in a group of men reporting a last negative HIV test result within the previous 12 months
uHIVunk – undiagnosed HIV in a group of men who never tested for HIV or whose last negative HIV test result is older than 12 months
uHIV – undiagnosed HIV in the combined group of men irrespective of the time of the last negative HIV test
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appears to test more frequently and be aware of risks.
Taking this into account, the probability is high that
many of them would have been tested again and diag-
nosed in the near future. It might also be that some of
them tested in the HIV window period and received a
false negative test result. To improve early HIV diagnosis
in this group, men with these characteristics presenting
for HIV testing should be offered laboratory testing with
4th generation HIV antigen/antibody tests to increase
the probability to detect recent infections. If sufficient
resources are available, even targeted PCR testing could
be considered if this subgroup can be identified among
the clients of the testing facilities, e.g. based on a com-
bined symptoms and behaviours score [28, 29].
The men with undiagnosed infection following a nega-
tive test within the past 12 months had high odds of
having used recreational drugs during their last anal sex
encounter and high odds of not discussing their HIV sta-
tus with the last anal sex partner(s) [30]. Because viral
load and transmissibility of HIV are very high during the
phase of acute HIV infection [31–33], many of their re-
cent sexual partners may have been at high risk for acquir-
ing HIV infection if they engaged in condomless anal
intercourse relying on an assumed negative HIV status. In
the literature, the associations between repeat testing and
risk behaviours are complex. Receiving a negative result
may trigger different reactions from reassurance in safe
practices to feeling lucky or invulnerable, or reinforce
risky behaviour that is associated with a subsequent higher
frequency of unprotected sex [34].
These findings clearly point to the need of recommending
more frequent testing in selected groups of MSM, especially
to those using recreational drugs. More importantly, the tes-
ters could be considered as primary target group for HIV
pre-exposure prophylaxis (PrEP) to avoid HIV infection in
the first place, as also suggested by other authors [35].
Approximately one-third of the men with undiagnosed
HIV in the Sialon II sample infrequently test for HIV, al-
though they tend to have multiple condomless anal sex
encounters. Higher proportions were observed particu-
larly in the four RDS cities, which may suggest that
more hidden subgroups within the MSM populations
were reached (see also Limitations). This, from a public
health perspective, is an advantage of this sampling
methodology compared to TLS method and probably to
National HIV surveillance systems as well. While the
study was not designed to answer the research question
on identifying characteristics and behaviours of undiag-
nosed HIV-infected participants, only number of partners
with whom condomless anal intercourse was practiced
and more frequent STI testing was associated with the
outcome variable (undiagnosed HIV infection) in this
group. While age was significantly and independently as-
sociated with being undiagnosed in this group, more
research will be necessary to characterize MSM living with
undiagnosed HIV infection who do not test frequently for
this infection in order to develop evidence-based interven-
tions to increase test uptake. However, in the bivariate
analysis we also found high odds for having been diag-
nosed with a STI during the last 12 months in this group.
This strongly suggests that contrary to guidelines and rec-
ommendations HIV testing had not been offered or not
been conducted in the context of these STI diagnoses. We
are unable to determine whether this missed opportunity
for an earlier diagnosis of HIV is related to a lack of dis-
cussion and disclosure of sexual orientation with the STI
test and treatment provider or to a lack of compliance
with testing guidelines by the STI treatment providers.
Partnership status and type of partner for last anal inter-
course were not significantly associated with undiagnosed
HIV, suggesting that condomless sex within steady part-
nerships may not always be as safe as people tend to as-
sume, particularly if HIV status has not been checked
mutually and/or if condomless anal sex is practiced con-
currently with non-steady partners.
Limitations
For correct interpretation of our findings it must be con-
sidered that we report on associations with undiagnosed
HIV infections in a very specific group. Factors associated
with undiagnosed HIV may partly be different from fac-
tors associated with transmission risk, because a part of
those who acquire HIV will be diagnosed and detected
early. For MSM who infrequently test for HIV it may be
difficult to detect behavioural correlates for their infection
risk because we asked for behaviours in the previous
6 months. The moment when these men acquired HIV
may be longer ago and their behaviour may have changed.
MSM who have never been tested for HIV may be under-
represented in our sample. Never tested MSM are often
less integrated into gay communities and rarely visit gay
venues; this explains why they would have a lower chance
to be recruited in our study, at least when considering the
cities where a TLS approach has been adopted to enrol
study participants [36]. This means that our uHIVunk
group may mainly represent pattern 2 testing (triggered
by health concerns not immediately related to acute HIV
disease or transmission risk awareness) and less pattern 3
testing. A further limitation is that HIV status knowledge
was based on self-reports and some participants may have
felt uncomfortable reporting their HIV status in the ques-
tionnaire. Underreporting of a positive HIV status would
have weakened any association we found between being
undiagnosed and other factors.
Conclusions
Our study findings reinforce the recommendations for
healthcare provider-initiated HIV testing when certain
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indicator diseases such as STIs are diagnosed. The find-
ings may also inform community-based low-threshold
HIV testing strategies such as home-collection sampling
and test promotion campaigns to reduce the proportion
of the hidden HIV epidemic. Such strategies should in-
clude certain elements of information (e.g. on the sensitiv-
ity of different tests during acute HIV infection), focus on
interpersonal skills and community norms (e.g. communi-
cation with sexual partners about serostatus) and highlight
additional risks associated with recreational drug use,
while recognising the diversity of MSM with undiagnosed
HIV across Europe. In addition, novel strategies such as
home-testing should be discussed in the light of safe-
guarding linkage to care [37]. Since data were collected in
different European cities, the findings allow for a high de-
gree of tailoring local prevention campaigns, i.e. develop-
ing targeted HIV and STI testing campaigns considering
the local contexts in both community-based HIV testing
and counselling and advice offered at such HIV testing
sites [38, 39].
More importantly, tailored strategies based on the
established HIV testing patterns should be embedded
within an overall combined prevention approach
[40], which should include the addition of PrEP to
the available effective prevention tools [40–42] for
instance for those MSM reporting condomless anal
sex with multiple partners in the last 6 months.
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